B. Riley Raises TG Therapeutics EPS Forecast
Summary
B. Riley has raised its Q4 2025 earnings per share estimate for TG Therapeutics (NASDAQ:TGTX) from $0.34 to $0.36. The company reported Q2 earnings of $0.17 per share, missing the consensus estimate of $0.32. Revenue for the quarter was $141.15 million, below the expected $147.76 million. Analysts project FY2026 earnings at $1.34 EPS, increasing to $4.42 EPS by FY2029. TG Therapeutics has a current market cap of $4.51 billion and a consensus rating of ‘moderate buy’ with a price target of $43.80. Market Beat
Impact Analysis
- Business Overview Analysis
- Core Business Model: TG Therapeutics is a biopharmaceutical company focused on developing and commercializing novel treatments for B-cell diseases. Its primary revenue streams are derived from the sales of its therapeutics.
- Market Position: The company has a competitive position with a moderate buy rating and a price target of $43.80, indicating positive analyst sentiment despite recent performance misses.
- Recent Events: The company missed its Q2 earnings and revenue estimates, which may temporarily impact investor sentiment and stock performance. However, the increase in future earnings projections suggests confidence in long-term growth prospects.
- Financial Statement Analysis
- Income Statement: The Q2 earnings per share of $0.17 and revenue of $141.15 million fell short of expectations, indicating challenges in current operations but potential for improvement with increased future earnings estimates.
- Key Financial Ratios:
- Profitability: Current margins are under pressure due to missed earnings, but future earnings growth suggests potential improvement.
- Liquidity & Solvency: The current analysis does not provide detailed balance sheet metrics, but the company’s market cap and consensus rating suggest adequate financial health.
- Efficiency: Revenue shortfall indicates potential inefficiencies that the company may need to address to meet future targets.
Overall, TG Therapeutics’ short-term financial performance may face scrutiny, but its long-term earnings projections point to potential growth opportunities. Investors may consider the raised earnings estimates as a positive signal, balanced against the immediate earnings miss risks. Market Beat
